DJIA51828.62 478.64
S&P 5007743.41 39.28
NASDAQ27068.72 129.34
Russell 20002837.55 1.98
German DAX25408.64 142.11
FTSE 10010695.25 15.26
CAC 408077.80 -3.63
EuroStoxx 506298.15 25.20
Nikkei 22566364.20 850.21
Hang Seng24510.09 -251.04
Shanghai Comp3888.37 -48.15
KOSPI7080.92 63.01
Bloomberg Comm IDX144.32 -1.62
WTI Crude-fut97.47 -2.49
Brent Crude-fut92.44 -1.85
Natural Gas3.25 -0.03
Gasoline-fut3.20 -0.12
Gold-fut4320.50 12.30
Silver-fut64.71 0.52
Platinum-fut1800.80 32.60
Palladium-fut1277.50 2.50
Copper-fut6.78 0.01
Aluminum-spot3195.00 0.00
Coffee-fut278.10 1.50
Soybeans-fut1320.00 3.50
Wheat-fut704.00 -1.75
Bitcoin84117.52 -69.89
Ethereum USD2693.28 10.46
Litecoin73.17 2.08
Dogecoin0.10 0.00
EUR/USD1.1381 -0.0007
USD/JPY158.79 0.50
GBP/USD1.3212 -0.0029
USD/CHF0.8289 0.0040
USD IDX101.04 -0.22
US 10-Yr TR5.167 0.005
GER 10-Yr TR3.6061 -0.0171
UK 10-Yr TR5.3528 -0.0129
JAP 10-Yr TR3.077 -0.005
Fed Funds4 0
SOFR3.88 0.01
High-rise commercial buildings

Sub Markets

Topics

Direct Investment  + Latest News  + M&As  | 
AmerisourceBergen, TPG Team Up to Buy OneOncology in $2.1B Deal

AmerisourceBergen, TPG Team Up to Buy OneOncology in $2.1B Deal

AmerisourceBergen (ABC), a global pharmaceutical services organization, and private equity firm TPG have agreed to acquire oncology practice group OneOncology from growth equity firm General Atlantic in a deal valued at $2.1 billion.

TPG will take a majority stake in Nashville-based OneOncology, while ABC is buying a minority interest for about $685 million in cash, or roughly 35% ownership. OneOncology’s affiliated practices, physicians and management team will also retain a minority interest in the company.

The transaction is expected to close by the end of September 2023.

“As we look ahead, we are excited to continue building the platform in partnership with TPG, a proven investor in the healthcare provider space, and AmerisourceBergen, a healthcare leader with significant capabilities and solutions for community oncology practices,” said Dr. Jeff Patton, Chief Executive Officer of OneOncology.

The agreement stipulates that beginning on the third anniversary of the closing TPG will have a put option under which TPG may require ABC to purchase all the other interests in the joint venture, including TPG’s interest, at a price equal to 19x OneOncology’s EBITDA.

ABC will have two one-year call options beginning on the third and fourth anniversary of the closing to purchase all the other interests in the joint venture, including TPG’s at a similar price.

The OneOncology deal is expected to contribute a few cents to adjusted profit in the first year after closing, AmerisourceBergen said.

According to OneOncology’s 2022 annual report, the company has 15 practices, 550 physicians, 940 providers and 200 corporate employees.

Connect

Inside The Story

TPGAmerisourceBergen OneOncology

About Joe Palmisano

Joe Palmisano is editorial director of Connect Money, where he oversees daily coverage of alternative assets, direct investments, financial advisory and the economy. He brings three decades of experience as a financial journalist, analyst and portfolio manager. Before joining Connect Money, Palmisano wrote for The Wall Street Journal, covering foreign exchange, global fixed-income and equity markets. He later served as a senior research analyst and portfolio manager, producing market analysis and managing foreign exchange and U.S. equity portfolios for FX Concepts. His work has also appeared in SFO Magazine and CMT Association publications. Palmisano earned a bachelor’s degree in finance from The American University and holds the Chartered Market Technician (CMT) designation and is a member of the CFA Institute.